Le Lézard
Classified in: Health, Science and technology
Subject: PLW

Zynx Health Awarded Patent for Computer-implemented Method of Analyzing CDS Documents


LOS ANGELES, Aug. 14, 2018 /PRNewswire/ -- Zynx Healthtm, a market leader in providing evidence- and experience-based clinical improvement solutions since 1996, today announced that the United States Patent and Trademark Office has issued US Patent 9,996,670 related to systems and methods for performing analytics, and in particular, on performing analytics on content, such as medical clinical decision support content. The technology is an integral component of Knowledge Analyzertm, Zynx Health's content management solution.

Zynx Health, part of Hearst Health, provides healthcare professionals with vital information and processes to guide care decisions and reduce complexity across the patient journey, in a way that leads to healthier lives. Zynx is the pioneer and market leader in evidence- and experience-based solutions that improve clinical and financial outcomes, patient engagement and technology performance. Zynx helps organizations exceed industry demands for the delivery of cost-effective, high-quality care. www.zynxhealth.com (PRNewsfoto/Zynx Health)

The patent covers a method of using supervised machine learning to identify the deficiencies and consistency of clinical content and guidelines. By validating CDS against current medical evidence, guidelines and performance measures, Knowledge Analyzer helps organizations reduce variation and improve outcomes.

"We appreciate the hard work of the Zynx data scientists who developed the algorithms and the clinical informatic teams who developed the training datasets, which today are helping healthcare systems standardize care and enhance patient outcomes," Jim Connolly, senior vice president of product and technology for Zynx Health. "Zynx remains committed to developing and delivering innovative solutions that reduce complexities for healthcare organizations and drive optimal clinical and financial performance."

Knowledge Analyzer is a revolutionary content management solution that enables clients to control and validate their content (e.g., order sets, care plans, policies) that resides within their EHR libraries and catalogs, to identify and close clinical gaps, create rules and alerts via checklists, maintain a single source of truth, avoid duplicate work, and prevent errors?all without requiring a system build or integration.

Zynx Health will be showcasing Knowledge Analyzer and other product offerings at the August 27-30 Epic Users Group Meeting in Verona, WI. Please schedule time with a Zynx Health team member to learn more about Knowledge Analyzer and other ways Zynx is using the latest technology to deliver solutions for post-acute care, nursing, and cloud-based applications.

About Zynx Health
Zynx Health, part of the Hearst Health network, provides healthcare professionals with vital information and processes that guide care decisions and reduce complexity across the entire patient journey in a way that leads to healthier lives for all. Zynx is a pioneer and market leader in evidence- and experience-based clinical solutions that help health systems improve patient outcomes, financial outcomes, clinical engagement and technology performance. With Zynx Health, healthcare organizations exceed industry demands for delivering high-quality care at lower costs under value-based reimbursement models. To learn more, visit zynxhealth.com or call 855.367.ZYNX.

About Hearst Health
The Hearst Health network includes FDB (First Databank), Zynx Health, MCG, Homecare Homebase, MedHOK, Hearst Health Ventures and the Hearst Health Innovation Lab (www.hearsthealth.com). Hearst also holds a minority interest in the precision medicine and oncology analytics company M2Gen. The mission of Hearst Health is to help guide the most important care moments by delivering vital information into the hands of everyone who touches a person's health journey. Each year in the U.S., care guidance from Hearst Health reaches 85 percent of discharged patients, 205 million insured individuals, 70 million home health visits and 3.2 billion dispensed prescriptions.

Media Contact:                                                 

Zynx Health Contact:

Michelle Ronan Noteboom                                 

Jeffrey Frater

Amendola Communications                                

Senior VP, Clinical Solutions & Strategy

512.426.2870                                                           

509.570.3822

[email protected]                            

[email protected]

 

SOURCE Zynx Health


These press releases may also interest you

at 22:00
The Global Health Innovative Technology (GHIT) Fund announced today a total investment of approximately JPY 1.64 billion (USD 10.8 million1) in four projects for the development of new drugs for malaria and neglected tropical diseases (NTDs).2  The...

at 21:00
Renova Therapeutics, a biotechnology company developing gene therapy-based treatments for cardiovascular and metabolic diseases, announced today that it has focused its development and commercialization efforts for its RT-100 and RT-200 gene...

at 20:05
Organovo Holdings, Inc. ("Organovo" or the "Company"), a clinical stage biotechnology company focused on developing novel treatment approaches based on demonstration of clinical promise in three-dimensional (3D) human tissues, today announced the...

at 20:00
Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology...

at 19:30
NCPDP announced today highlights from its 2024 Annual Technology & Business Conference, Innovation Starts Here. "NCPDP's standards and guidance are inherently innovative, and the work we continue to do will expand interoperability to support the...

at 19:25
Edwards Lifesciences today announced the European launch of the SAPIEN 3 Ultra RESILIA valve, the only transcatheter aortic heart valve to incorporate the company's breakthrough RESILIA tissue technology, designed to extend the valve's durability.*...



News published on and distributed by: